ABOUT US

Lentistem® Biotech is an R&D centred medical biotechnology company which designs and produces therapeutic lentiviral vectors. Our MISSION is to develop new technologies to improve the efficacy and safety of cancer immunotherapy (CAR-T cells). Our team is working in collaboration with several hospitals, academic labs and government agencies in Spain to create cost-effective and precise advanced gene-based therapies. We also offer our expertise in lentiviral-based gene delivery systems to provide cutting-edge tools for basic research. The company has exclusive license to multiple technologies, which are currently being used in 18 labs worldwide and cited in more than 70 peer-reviewed scientific publications.

We have state-of-art facilities for molecular analysis, cell biology small animal research and cell-culture facilities with P2-level safety standards to produce the highest grade viral vectors.

Miguel García Toscano

(PhD, MBA)

Verónica Ayllón Cases

(PhD)

Juan Antonio Marchal

(Full Professor)

Houria Boulaiz

(PhD)

Vaibah Bhatia

(PhD)

Juan José Díaz Mochón

(PhD)

Pablo Galindo

(Full Professor)